We are live on ! Find out more
LYEL icon

Lyell Immunopharma
LYEL

77 hedge funds and large institutions have $662M invested in Lyell Immunopharma in 2021 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 27 increasing their positions, 11 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

145% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 11

136% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 11

24% more funds holding

Funds holding: 62 → 77 (+15)

0.05% more ownership

Funds ownership: 1.72% → 1.78% (+0.05%)

33% less funds holding in top 10

Funds holding in top 10: 6 → 4 (-2)

46% less capital invested

Capital invested by funds: $1.22B → $662M (-$559M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $148K

Holders
77
Holders Change
+15
Holders Change %
+24.19%
% of All Funds
1.18%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.06%
New
26
Increased
27
Reduced
11
Closed
11
Calls
–
Puts
$148K
Net Calls
-$148K
Net Calls Change
-$148K

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$16.5M
2
E
Ergoteles
New York
+$11.2M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$7.62M
4
BlackRock
BlackRock
New York
+$6.38M
5
AP
Adero Partners
California
+$5.48M

Top Sellers

1
HA
HHLR Advisors
Cayman Islands
-$34.8M
2
DIG
Dragoneer Investment Group
California
-$14.8M
3
Federated Hermes
Federated Hermes
Pennsylvania
-$3.5M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$1.9M
5
MM
MWG Management
British Virgin Islands
-$1.52M
Name Holding Trade Value Shares
Change 		Change in
Stake
Manulife (Manufacturers Life Insurance)
76
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$135 +$31.2K +140 +19%
HA
77
HHLR Advisors
Cayman Islands
– -$34.8M -117,448 Closed
MCPPUI
78
MIC Capital Partners (Public) (US) IM
United Arab Emirates
– -$19.5M -66,000 Closed
DIG
79
Dragoneer Investment Group
California
– -$14.8M -50,000 Closed
Balyasny Asset Management
80
Balyasny Asset Management
Illinois
– -$1.9M -6,427 Closed
CCM
81
CAAS Capital Management
New York
– -$1.48M -5,000 Closed
MCM
82
Moore Capital Management
New York
– -$438K -1,478 Closed
GCM
83
Ghisallo Capital Management
Massachusetts
– -$222K -750 Closed
WMSA
84
Weiss Multi-Strategy Advisers
New York
– -$218K -735 Closed
SG Americas Securities
85
SG Americas Securities
New York
– -$157K -531 Closed
MIM
86
MetLife Investment Management
New Jersey
– -$153K -516 Closed
MLICM
87
Metropolitan Life Insurance Company (MetLife)
New York
– -$116K -390 Closed
Wells Fargo
88
Wells Fargo
California
– -$892 -4 -67%
1 2 3
4

LYEL Hedge Fund Activity: Q4 2021 in Review

77 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Lyell Immunopharma (LYEL) for Q4 2021, worth a combined $662M — down 46% from $1.22B a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new LYEL positions and 11 closed out — a net gain of 15 holders — while 27 added to existing stakes and 11 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $16.5M. The largest seller was HHLR Advisors, exiting entirely with an estimated $34.8M sold.

  • 77 institutional investors held Lyell Immunopharma (LYEL) as of Q4 2021, up from 62 in Q3 2021.
  • Funds reported $662M of Lyell Immunopharma stock for Q4 2021, down 46% quarter-over-quarter.
  • 26 funds opened new Lyell Immunopharma positions in Q4 2021 and 11 closed out, a net change of +15 holders.
  • The largest Lyell Immunopharma buyer in Q4 2021 was T. Rowe Price Associates, an estimated $16.5M added.
  • The largest Lyell Immunopharma seller in Q4 2021 was HHLR Advisors, an estimated $34.8M sold.

Based on aggregated 13F filings for Q4 2021.